SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union

SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been ...
Manufacturers' Monthly

EU backs Vaxxas patch-based flu vaccine

Vaxxas has been awarded a tender by the European Health and Digital Executive Agency to help develop next-generation ...
Healthcare Packaging

There’s a MAP for That: How Microneedle Patches Could Change Cold Chain, Drug Delivery, and Material Requirements for Biopharmaceuticals

As shelf-stable microarray patch (MAP) platforms move through development and clinical work, a ‘packaging first’ mentality is needed for industry-wide adoption.
Contract Pharma

EU Selects SK bioscience, IDT Biologika, Vaxxas for Next-Gen Flu Vaccine Development

SK bioscience, IDT Biologika, and Vaxxas will collaborate on a next-generation influenza vaccine development initiative.
Devdiscourse

Nanoparticle and AI-driven vaccines target broad protection against emerging threats

Read more about Nanoparticle and AI-driven vaccines target broad protection against emerging threats on Devdiscourse ...